<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activating mutations in Kras are the most frequent mutations in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>They define a subset of patients who do not respond to current therapies and for whom prognosis is poor </plain></SENT>
<SENT sid="2" pm="."><plain>Oncogenic Kras has been shown to deregulate numerous signaling pathways of which the most intensively studied are the Ras/extracellular signal-regulated kinase cascade and the <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase (PI3K)/Akt cascade </plain></SENT>
<SENT sid="3" pm="."><plain>However, to date, there are no effective targeted therapies in the clinic against Kras-mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report that the β-<z:chebi fb="0" ids="24163">galactoside</z:chebi>-binding protein (βGBP) cytokine, a physiologic inhibitor of class I PI3Ks, is a potent activator of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in Kras-mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, even when coharboring mutant-activated PIK3CA </plain></SENT>
<SENT sid="5" pm="."><plain>Our study unveils an elective route to intrinsic and extrinsic <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, which involves the cytoskeleton </plain></SENT>
<SENT sid="6" pm="."><plain>Early events are inhibition of PI3K activity and Rac-independent actin rearrangement assignable to <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> changes at the plasma membrane </plain></SENT>
<SENT sid="7" pm="."><plain>Cyclin E deregulation, arrest of DNA synthesis, and checkpoint kinase 2 activation underscore events critical to the activation of an intrinsic apoptotic program </plain></SENT>
<SENT sid="8" pm="."><plain>Clustering of CD95/Fas <z:hpo ids='HP_0011420'>death</z:hpo> receptors underscore events critical to the activation of extrinsic <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:mp ids='MP_0003815'>nude</z:mp> mice, we present the first evidence that xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development is strongly inhibited by Hu-r-βGBP </plain></SENT>
<SENT sid="10" pm="."><plain>Taken together, our results open a new therapeutic opportunity to a subset of patients refractive to current treatments </plain></SENT>
<SENT sid="11" pm="."><plain>This first demonstration of therapeutic efficacy against Kras-mutant <z:hpo ids='HP_0003003'>colon cancer</z:hpo> suggests that Hu-r-βGBP may also be therapeutically effective against other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> harboring activating Ras mutations as well as PIK3CA mutations </plain></SENT>
</text></document>